BioSpace News Archive

Highlights: Phase I/II trial agreement with Fiona Stanley Hospital (Burns Unit) in Perth Western Australia Study led by world leading burn treatment specialists Study will assess safety and efficacy of RECCE ® 327 against a broad range of infectious disease on chronic burn wounds in up to 30 patients

Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that Dr. Henry Smith has accepted the role of Chairman of the Scientific Advisory Board. Dr. Henry Smith has over 50 years’ experience in Healthcare. Dr. Smith has worked to develop novel technologies to serve the healthcare industry, including one of the first CEA (Carcinoma Embryonic Antigen) tests for detecting cancer.

Technical Committee Formed to Advance Adoption and Development of XBAR® Technologies in 5G, Wi-Fi and Other Growth Markets Company Appoints Larry Larson, PhD, Jianming Jin, PhD, and Gabriel Rebeiz, PhD, to Newly Formed Committee

HealthyWomen, the nation’s leading independent, nonprofit health information source for women, and Myovant Sciences, a healthcare company focused on redefining care for women and for men, launched “Voices of Periods,” a storytelling initiative to elevate conversations about menstrual health by sharing diverse, personal stories of the real-life impact of menstrual stigma.

Microvi announced that they have been awarded a $1.12 million grant from the National Institutes of Health to apply machine learning and bioinformatics to develop a new generation of biological treatment processes.

Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the company’s participation at upcoming healthcare investor conferences:

Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, announced that it has completed the sale of an additional 825,000 shares of common stock,

Semeon Analytics , an ATW Tech Inc. company, is pleased to announce its most recent contract with a branch of the U.S. military to apply its technology to better understand how complex composite materials can fail and therefore facilitate the development of processes that safeguard components assembled with these new materials.

C2Dx Inc., a medical device company that invests in and refines the delivery of valuable, niche products to propel their growth, has acquired the T/Pump product line from Stryker. The T/Pump is the second product line for C2Dx, joining its initial acquisition of the STIC Intra-Compartmental Pressure Monitor.

- binx molecular point-of-care platform poised to transform care for chlamydia and gonorrhea, the two most tested for sexually-transmitted infections -